Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 75 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is D  [Clear All Filters]
Journal Article
Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW.  2018.  5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.. J Antibiot (Tokyo). 71(11):950-961.
Viladomiu M, Metz ML, Lima SF, Jin W-B, Chou L, Guo C-J, Diehl GE, Simpson KW, Scherl EJ, Longman RS.  2021.  Adherent-invasive E. coli metabolism of propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation.. Cell Host Microbe.
Hassan-Zahraee M, Ye Z, Xi L, Baniecki MLynn, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J et al..  2021.  Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.. Inflamm Bowel Dis.
Yarur AJ, Deepak P, Casteele NVande, Battat R, Jain A, Okada L, Osterman M, Regueiro M.  2021.  Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.. Dig Dis Sci. 66(10):3563-3569.
Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Casteele NVande et al..  2021.  Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.. Clin Gastroenterol Hepatol. 19(3):511-518.e6.
Battat R, Dulai PS, Casteele NVande, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J et al..  2019.  Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.. Inflamm Bowel Dis. 25(2):410-420.
DeFilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EJ, Sockolow R.  2015.  Cerebral venous thrombosis in inflammatory bowel disease.. J Dig Dis. 16(2):104-8.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ.  2016.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.. Curr Gastroenterol Rep. 18(3):13.
DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ.  2016.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.. Curr Gastroenterol Rep. 18(3):13.
Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SGuk et al..  2007.  Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.. ISME J. 1(5):403-18.
Longman RS, Diehl GE, Victorio DA, Huh JR, Galan C, Miraldi ER, Swaminath A, Bonneau R, Scherl EJ, Littman DR.  2014.  CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.. J Exp Med. 211(8):1571-83.
Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A.  2019.  Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.
Longman RS, Braun D, Pellegrini S, Rice CM, Darnell RB, Albert ML.  2007.  Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation.. Blood. 109(3):1113-22.
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al..  2021.  Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.
Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD et al..  2015.  The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.. Inflamm Bowel Dis. 21(12):2886-96.
Yang E, Panaccione N, Whitmire N, Dulai PS, Casteele NVande, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R et al..  2020.  Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.. Aliment Pharmacol Ther. 51(11):1031-1038.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al..  2020.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al..  2019.  Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.